Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021
September 10 2021 - 7:00AM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced
that the Company will host a virtual investor event to review the
rebastinib and vimseltinib clinical data to be presented at the
upcoming European Society for Medical Oncology (ESMO) Congress 2021
on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET.
Deciphera’s senior executive team will be joined by the
following key opinion leaders at the event:
- Dr. Robert L. Coleman, M.D., FACOG, FACS, Gynecologic
Oncologist and Chief Scientific Officer at US Oncology
Research
- William D. Tap, M.D., Chief of the Sarcoma Medical Oncology
Service at Memorial Sloan Kettering Cancer Center
A live webcast of the event may be accessed through the
“Investors” section of Deciphera’s website at www.deciphera.com. A
replay of the webcast will be available following the event.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering,
developing and commercializing important new medicines to improve
the lives of people with cancer. We are leveraging our proprietary
switch-control kinase inhibitor platform and deep expertise in
kinase biology to develop a broad portfolio of innovative
medicines. In addition to advancing multiple product candidates
from our platform in clinical studies, QINLOCK® is Deciphera’s
FDA-approved switch-control kinase inhibitor for the treatment of
fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also
approved for fourth-line GIST in Australia, Canada, China, Hong
Kong, and Taiwan. For more information, visit www.deciphera.com and
follow us on LinkedIn and Twitter (@Deciphera).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210910005108/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112
Media: David Rosen Argot Partners David.Rosen@argotpartners.com
212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From May 2024 to Jun 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jun 2023 to Jun 2024